Protein Expression Publications

  1. Unger T., Oren Z. & Shai Y. (2001). The effect of cyclization of magainin 2 and melittin analogues on structure, function, and model membrane interactions: Implication to their mode of action.  Biochemistry. 2001 May 29 , 40 (21):6388-6397.
  2. Unger T., Juven-Gershon T., Moallem E., Berger M., Sionov R., Lozano G., Oren M. & Haupt Y. (1999). Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2.  EMBO Journal. 1999 Apr 1 , 18 (7):1805-1814.
  3. Unger T., Sionov R., Moallem E., Yee C., Howley P., Oren M. & Haupt Y. (1999). Mutations in serines 15 and 20 of human p53 impair its apoptotic activity.  Oncogene. 1999 May 27 , 18 (21):3205-3212.
  4. Mor F., Boccaccio G. & Unger T. (1998). Expression of autoimmune disease-related antigens by cells of the immune system.  Journal of Neuroscience Research. 1998 Oct 15 , 54 (2):254-262.
  5. Juven-Gershon T., Shifman O., Unger T., Elkeles A., Haupt Y. & Oren M. (1998). The Mdm2 oncoprotein interacts with the cell fate regulator numb.  Molecular and Cellular Biology. 1998 Jul , 18 (7):3974-3982.
  6. Fiscella M., Zambrano N., Ullrich S. J., Unger T., Lin D., Cho B., Mercer W. E., Anderson C. W. & Appella E. (1994). The carboxy-terminal serine 392 phosphorylation site of human p53 is not required for wild-type activities.  Oncogene. 1994 Nov , 9 (11):3249-57.
  7. Unger T., Mietz J. A., Scheffner M., Yee C. L. & Howley P. M. (1993). Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression.  Molecular and Cellular Biology. 1993 Sept , 13 (9):5186-94.
  8. Unger T., Nau M. M., Segal S. & Minna J. D. (1992). p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer.  EMBO Journal. 1992 Apr , 11 (4):1383-90.
  9. Mietz J. A., Unger T., Huibregtse J. M. & Howley P. M. (1992). The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein.  EMBO Journal. 1992 Dec , 11 (13):5013-20.
  10. Unger T. & Shaul Y. (1990). The X protein of the hepatitis B virus acts as a transcription factor when targeted to its responsive element.  EMBO Journal. 1990 Jun 1 , 9 (6):1889-1895.
  11. MOCK B., Givol D., DHOOSTELAERE L., HUPPI K., SELDIN M., GURFINKEL N., Unger T., POTTER M. & MUSHINSKI J. (1988). Mapping of the bcl-2 oncogene on mouse chromosome 1.  Cytogenetics and Cell Genetics. 1988, 47 (1-2):11-15.
  12. Gurfinkel N., Unger T., Givol D. & Mushinski J. F. (1987). Expression of the bcl2 gene in mouse B lymphocytic cell lines is differentiation stage specific.  European Journal of Immunology. 1987, 17 (4):567-570.
  13. KATZIR N., RECHAVI G., COHEN J., Unger T., SIMONI F., SEGAL S., Cohen D. & Givol D. (1985). 'Retroposon' insertion into the cellular oncogene c-myc in canine transmissible venereal tumor.  Proceedings of the National Academy of Sciences of the United States of America. 1985, 82 (4):1054-1058.
  14. COHEN J., Unger T., RECHAVI G., Canaani E. & Givol D. (1983). Rearrangement of the oncogene c-mos in mouse myeloma NSI and hybridomas.  Nature. 1983, 306 (5945):797-799.